These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 28103444)

  • 21. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
    Mancuso ME; Reding MT; Negrier C; Kerlin BA; Rangarajan S; Simpson ML
    Thromb Haemost; 2021 Aug; 121(8):1079-1086. PubMed ID: 33296943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The first recombinant FVIII produced in human cells--an update on its clinical development programme.
    Valentino LA; Negrier C; Kohla G; Tiede A; Liesner R; Hart D; Knaub S
    Haemophilia; 2014 Jan; 20 Suppl 1():1-9. PubMed ID: 24330348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. First and second generation recombinant factor VIII concentrates in previously untreated patients: recovery, safety, efficacy, and inhibitor development.
    Lusher JM
    Semin Thromb Hemost; 2002 Jun; 28(3):273-6. PubMed ID: 12098088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program.
    Lissitchkov T; Klukowska A; Pasi J; Kessler CM; Klamroth R; Liesner RJ; Belyanskaya L; Walter O; Knaub S; Bichler J; Jansen M; Oldenburg J
    Ther Adv Hematol; 2019; 10():2040620719858471. PubMed ID: 31263528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G; Spranger T; Brackmann HH
    Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
    Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
    Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A-Final efficacy and safety results from the NuProtect study.
    Mathias M; Abraham A; Belletrutti MJ; Carcao M; Carvalho M; Chambost H; Chan AKC; Dubey L; Ducore J; Gattens M; Gresele P; Gruel Y; Guillet B; Jiménez-Yuste V; Kitanovski L; Klukowska A; Lohade S; Mancuso ME; Oldenburg J; Pollio B; Sigaud M; Vilchevska K; Wu JKM; Jansen M; Belyanskaya L; Walter O; Knaub S; Neufeld EJ
    Eur J Haematol; 2023 Oct; 111(4):544-552. PubMed ID: 37439123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress in the treatment of bleeding disorders.
    Bergman GE
    Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Turoctocog alfa for the treatment of hemophilia A.
    Haddley K
    Drugs Today (Barc); 2014 Feb; 50(2):121-31. PubMed ID: 24619589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibitors in Severe Hemophilia A: 25-Year Experience in Slovakia.
    Batorova A; Jankovicova D; Morongova A; Bubanska E; Prigancova T; Horakova J; Machyniakova M; Cervenka J; Chandoga J; Böhmer D; Mistrik M
    Semin Thromb Hemost; 2016 Jul; 42(5):550-62. PubMed ID: 27235830
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of current literature on second-generation, sucrose-formulated, full-length recombinant factor VIII.
    Konigs C; von Hentig N
    Drugs Today (Barc); 2009 Jul; 45(7):549-61. PubMed ID: 19834631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First and next generation native rFVIII in the treatment of hemophilia A. What has been achieved? Can patients be switched safely?
    Suiter TM
    Semin Thromb Hemost; 2002 Jun; 28(3):277-84. PubMed ID: 12098089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A.
    Shapiro AD; Schoenig-Diesing C; Silvati-Fidell L; Wong WY; Romanov V
    Haemophilia; 2015 Nov; 21(6):791-8. PubMed ID: 26010678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Octocog alfa (Advate®): a guide to its use in hemophilia A.
    Keating GM; Dhillon S
    BioDrugs; 2012 Aug; 26(4):269-73. PubMed ID: 22759264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Turoctocog alfa: an evidence-based review of its potential in the treatment of hemophilia A.
    Takedani H; Hirose J
    Drug Des Devel Ther; 2015; 9():1767-72. PubMed ID: 25848213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies.
    Santagostino E; Young G; Carcao M; Mannucci PM; Halimeh S; Austin S
    Expert Rev Hematol; 2018 Feb; 11(2):87-97. PubMed ID: 29258406
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of Nuwiq
    Zozulya N; Kessler CM; Klukowska A; von Depka M; Hampton K; Hay CRM; Jansen M; Bichler J; Knaub S; Rangarajan S
    Haemophilia; 2018 Jan; 24(1):70-76. PubMed ID: 29048712
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A.
    Castaman G; Linari S
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):143-151. PubMed ID: 29257899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
    Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
    Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allergic reaction in a cohort of haemophilia A patients using plasma-derived factor VIII (FVIII) concentrate is rare and not necessarily triggered by FVIII.
    Montalvão SA; Tucunduva AC; Siqueira LH; Sambo AL; Medina SS; Ozelo MC
    Haemophilia; 2015 Jul; 21(4):e281-5. PubMed ID: 25929310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.